TREATMENT OF TRIPLE NEGATIVE BREAST CANCER WITH TARGETED TGF-B INHIBITION

The present disclosure relates generally to methods for treating a patient diagnosed with triple negative breast cancer (TNBC), involving identifying a patient likely to respond to treatment via targeted TGF-β inhibition with an anti-TGFβ agent, and treating the subject with the anti-TGFβ agent....

Full description

Saved in:
Bibliographic Details
Main Authors LOCKE George, DUSSAULT Isabelle
Format Patent
LanguageEnglish
Spanish
Published 28.04.2021
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
MEASURING
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PHYSICS
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
TESTING
Online AccessGet full text

Cover

More Information
Summary:The present disclosure relates generally to methods for treating a patient diagnosed with triple negative breast cancer (TNBC), involving identifying a patient likely to respond to treatment via targeted TGF-β inhibition with an anti-TGFβ agent, and treating the subject with the anti-TGFβ agent. La presente descripción se refiere en general a métodos para tratar un paciente diagnosticado con cáncer de mama triple negativo (TNBC), que comprende identificar un paciente que probablemente responda al tratamiento mediante inhibición dirigida de TGF-ß con un agente anti-TGFß, y tratar al sujeto con el agente anti-TGFß.
Bibliography:Application Number: MX20210002006